Compare Lululemon Athletica Inc (LULU) vs Moderna, Inc. (MRNA) Price & Performance

Lululemon trades at $116.79, up 0.4% on the day, with a bearish technical signal but strong fundamentals including a 13.03% net margin and 32.03% ROE. Recent earnings beats and a $30M investment in nylon recycling startup Syntetica highlight growth initiatives, though the stock faces headwinds from North American weakness and a class-action lawsuit over tariff costs. The current price sits near pivot point resistance at $117.

The outlook is mixed: valuation metrics like a 9.42 P/E suggest potential upside to the $129.29 consensus target, but bearish technicals and competitive pressures pose risks. Investment opportunity lies in robust cash flow and buyback potential, while key risks include brand controversies and macroeconomic sensitivity.

Moderna (MRNA) trades at $60.47, down 2.18% on the day, with a mixed technical outlook showing a bullish overall signal but bearish moving averages. The company reported a net loss of -$2.82B in 2025, with revenue declining to $1.92B, though it has beaten EPS estimates in recent quarters. Recent news highlights progress in its cancer pipeline, including a Phase 1 study for mRNA-4200, and an EU contract for its RSV vaccine.

The outlook remains speculative with high execution risk as Moderna transitions beyond COVID-19 vaccines. While pipeline advancements offer long-term potential, persistent losses and negative margins pose significant challenges. Analyst consensus is cautious with a $49 price target, suggesting limited near-term upside amid ongoing fundamental headwinds.